Whole Genome Sequencing to Survey Genetic Changes in Stable CHO Cell Lines
ESACT
May 14, 2017
Chinese hamster ovary (CHO) cells represent the most frequently applied host cell system for industrial manufacturing of recombinant protein therapeutics. Generating and identifying high producing clones in a fast and efficient way such that they do not lose their expression capability over time has been a major focus of the...

Learn More
SELEXIS SUREscan: De-risking Cell Bank Generation with Comprehensive Genomic Analysis
PEACE
September 29, 2015
Recombinant therapeutic protein production processes must guarantee a sufficiently small variability in the product quality. To keep this variability low, it is critical to run the process in a totally reproducible way. This requires controlling all cultivation parameters. The use of new analyzers, generating new data sets, besides cultivation parameters...

Learn More
CHO Cell Library for the Selection of Improved Recombinant Therapeutic Protein Production Clones
Cell Line Development & Engineering (WINNER, BEST POSTER)
May 29, 2013
In an effort to improve product yield of mammalian cell lines, we have previously demonstrated that our proprietary DNA elements, Selexis Genetic Elements (SGEs), increase the transcription of a given transgene1, thus boosting the overall expression of a therapeutic protein drug in mammalian cells. However, there are additional cellular bottlenecks,...

Learn More
Engineering CHO Cell Lines for Enhanced Production of Recombinant Proteins
June 17, 2011
The development of new mammalian expression platforms represents an ongoing need for advancing biophar-maceuticals towards human clinical trials. In an effort to address this issue, we have developed new solutions for more efficient identification of individ-ual protein candidates in stably trans-fected CHO cells. We have shown that the combination of...

Learn More